Related Experiment Video
Updated: May 18, 2026

05:26
Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications
Published on: April 13, 2022
[Preparation of basic fibroblast growth factor chitosan microsphere and its properties]
Wei Chen1, Zhongqian Liu, Yuanhui Yue
1Department of Orthopaedics, People's Hospital of Fengjie County, Fengjie Chongqing 404600, PR China.
Summary
Basic fibroblast growth factor (bFGF) chitosan microspheres were prepared using a cross-linking-emulsion method. These microspheres demonstrate sustained bFGF release over 24 days with high encapsulation efficiency, indicating their potential for controlled drug delivery.
Area of Science:
- Biomaterials Science
- Drug Delivery Systems
- Polymer Chemistry
Context:
- Chitosan is a biocompatible and biodegradable polysaccharide widely explored as a carrier material in drug delivery.
- Basic fibroblast growth factor (bFGF) is a crucial protein involved in cell growth, proliferation, and wound healing.
- Controlled release of therapeutic proteins like bFGF is essential for maintaining therapeutic efficacy and minimizing adverse effects.
Purpose:
- To develop and characterize basic fibroblast growth factor (bFGF) loaded chitosan microspheres using a cross-linking-emulsion method.
- To evaluate the physicochemical properties, including particle size, morphology, drug loading, and encapsulation efficiency.
- To investigate the in vitro release profile of bFGF from the prepared chitosan microspheres over an extended period.
Summary:
- bFGF-loaded chitosan microspheres were successfully prepared via a cross-linking-emulsion technique, yielding particles with sizes ranging from 20.312 to 24.152 micrometers.
- The microspheres exhibited a spherical morphology with a smooth surface and uniform distribution, and demonstrated high drug loading (7.57 ± 0.34 mg/g) and encapsulation efficiency (95.14% ± 1.58%).
- An initial burst release of 18.08% was observed, followed by sustained release of bFGF for 24 days, reaching 82.05% cumulative release, with bFGF levels increasing to 820.45 ± 21.34 ng/mL at day 24.
Impact:
- The developed bFGF chitosan microspheres offer a promising platform for sustained delivery of therapeutic proteins.
- The ease of preparation and favorable release characteristics lay the foundation for further in vivo studies and potential clinical applications.
- This study contributes to the field of biodegradable drug delivery systems, highlighting the potential of chitosan-based formulations for protein therapeutics.

